Trials / Completed
CompletedNCT07336485
Forced Diuresis After Flexible Ureteroscopy for Medium-Sized Renal Stones
Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Management of Medium Sized Renal Stones
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2,000 (actual)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized controlled clinical trial evaluated whether furosemide-assisted forced diuresis during flexible ureteroscopy reduced the residual fragment rate and improved the stone-free rate after flexible ureteroscopy for management of medium sized renal stones measuring up to 30 millimeters. Adult patients undergoing flexible ureteroscopy for renal stones were randomized into two parallel groups: an experimental group that received intravenous furosemide during the procedure and a control group that received standard perioperative and postoperative care without furosemide. Stone-free status and residual fragments were assessed using non-contrast computed tomography performed four weeks after the procedure, and residual fragments were classified by fragment size. Secondary outcomes included operative time, length of hospital stay, postoperative complications, total urine output in the first 24 hours, and the need for additional treatments for significant residual stones.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Furosemide | Intravenous furosemide was administered as a total dose of 40 milligrams during the procedure, divided into 20 milligrams given 5 minutes after induction of anesthesia and 20 milligrams given 30 minutes after the start of the procedure. |
| OTHER | Standard Care After Flexible Ureteroscopy Without Furosemide | Participants received standard perioperative and postoperative management after flexible ureteroscopy without administration of furosemide or any other diuretic medication. |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
- First posted
- 2026-01-13
- Last updated
- 2026-01-13
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07336485. Inclusion in this directory is not an endorsement.